Evidence map›Paper›PMID 38944197›Full record

ArticleThe journal of allergy and clinical immunology. In practice2024

Mammalian Meat Allergy and IgE to Alpha-Gal in Central Virginia: Findings From a COVID-19 Vaccine and Patient Cohort.

Nathan E Richards, Samuel M Ailsworth, Lisa J Workman, Pamela Schoppee Bortz, Jaimin Patel, Matthew MacCallum, Glenda Canderan, Deborah Murphy, Lyndsey M Muehling, Emily C McGowan and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Pre-clinical strategies and emerging technologies driving advances in the alpha-gal syndrome.Allergology international : official journal of the Japanese Society of Allergology · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nathan E RichardsDivision of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Va.
Samuel M AilsworthDivision of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Va.
Lisa J WorkmanDivision of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Va.
Pamela Schoppee BortzDivision of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Va.
Jaimin PatelDivision of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Va.
Matthew MacCallumDivision of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Va.
Glenda CanderanDivision of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Va.
Deborah MurphyDivision of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Va.
Lyndsey M MuehlingDivision of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Va.
Emily C McGowanDivision of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Va.
Judith A WoodfolkDivision of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Va.
Alexandra KadlDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia, Charlottesville, Va; Department of Pharmacology, University of Virginia, Charlottesville, Va.
Thomas A E Platts-MillsDivision of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Va.
Jeffrey M WilsonDivision of Allergy and Clinical Immunology, Department of Medicine, University of Virginia, Charlottesville, Va. Electronic address: jmw2gc@virginia.edu.

Funding

IgE antibodies to the mammalian oligosaccharide galactose-alpha-1, 3-galactose (alpha-gal): immunology, epidemiology and relevance to allergic and inflammatory diseaseR37AI020565 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI THOMAS A. PLATTS-MILLS · 1992 to 2026
$8.4M
DUST MITE, COCKROACH AND CAT ALLERGENS IN HOUSES/ASTHMAR01AI020565 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI PLATTS-MILLS, THOMAS A. · 1985 to 2017
$7.1M
Investigation of the prevalence, presentation and immunologic features of the α-Gal syndrome in a high-risk cohort not recruited on the basis of allergic diseaseR21AI166861 · NIAID · UNIVERSITY OF VIRGINIA · PI WILSON, JEFFREY M · 2022 to 2023
$444k
Exploring Amplified Th1 Responses and a Role for the IgE/Interferon Axis in Allergic Asthmatics Infected with RhinovirusR21AI138077 · NIAID · UNIVERSITY OF VIRGINIA · PI WOODFOLK, JUDITH A · 2019 to 2020
$437k
Immune Programs and Related T Cell Mechanisms of Pulmonary Complications After COVID-19 IllnessR56AI178669 · NIAID · UNIVERSITY OF VIRGINIA · PI WOODFOLK, JUDITH A · 2023 to 2023
$410k
NIAID NIH HHS R01 AI020565NIAID NIH HHS R21 AI138077NIAID NIH HHS R21 AI166861NIAID NIH HHS R37 AI020565NIAID NIH HHS R56 AI178669
6 · The paper itself

Abstract

backgroundIgE to galactose-alpha-1,3-galactose (alpha-gal) is linked to tick bites and an important cause of anaphylaxis and urticarial reactions to mammalian meat. The alpha-gal syndrome (AGS) is recognized as being common in the southeastern United States. However, prevalence studies are lacking and open questions remain about risk factors and clinical presentation of alpha-gal sensitization.

objectiveHere we characterized the prevalence as well as the presentation and risk factors of AGS and alpha-gal IgE sensitization in adults in central Virginia recruited without regard to the history of allergic disease.

methodsAdults in central Virginia, primarily University of Virginia Health employees, were recruited as part of a COVID-19 vaccine study. Subjects provided at least one blood sample and answered questionnaires about medical and dietary history. We used ImmunoCAP for IgE assays and assessed the ABO blood group by reverse typing using stored serum. We also investigated biobanked serum from COVID-19 patients.

resultsMedian age of the 267 enrollees was 42 years, 76% were female, and 43 (16%) were sensitized to alpha-gal (cutoff of 0.1 IU/mL), of which mammalian meat allergy was reported by seven (2.6%). Sensitized subjects (1) were older, (2) had higher total IgE levels but a similar frequency of IgE to common respiratory allergens, and (3) were more likely to report tick bites than were nonsensitized subjects. Among those who were sensitized, alpha-gal IgE levels were higher among meat-allergic than nonallergic subjects (geometric mean, 9.0 vs 0.5 IU/mL; P < .001). Mammalian meat and dairy consumption was common in individuals with low-level sensitization.

conclusionIn central Virginia, AGS is a dominant cause of adult food allergy with a prevalence approaching or exceeding 2%.

Indexed as

COVID-19Food HypersensitivityImmunoglobulin EAdultAgedAllergensAnimalsCohort StudiesCOVID-19 VaccinesDisaccharidesFemaleHumansMaleMeatMiddle AgedPrevalenceAllergensCOVID-19 VaccinesDisaccharidesgalactosyl-(1-3)galactoseImmunoglobulin EAlpha-galCOVID-19Food allergyIgEMammalian meat allergyMeat allergyRed meatTicks

Identifiers

PMID38944197
PMCPMC13063161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.